Pay in 4 interest-free payments of $7.38 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
The 3 to 8 percentage point advantage over competitors in clinical data is a direct reflection of this additional mechanism of action
28 Friedmann AngeliJ
For MASH and liver disease Survodutide has Phase 2 data published in the NEJM showing 62% MASH resolution at the 4.8 mg dose, 62% liver fat reduction at the 6.0 mg dose, and meaningful fibrosis improvement
30 mg option Weekly 30 mg vial 10 units SQ once weekly 30 mg / 3 ml
Medication shipping is included for compounded GLP-1s and non-GLP-1 prescriptions filled by Founds pharmacy partners
Overall, there were no differences observed between dose groups, but statistical power was limited due to the small sample size in this study
US$ 24.62
US$ 28.51
US$ 28.80
US$ 28.61
